Sequential Bevacizumab-based therapy in metastatic colorectal cancer (mCRC): results of a treatment sequencing cost analysis

被引：0
|
作者：
Rautenberg, T. [1 ]
Siebert, U. [2 ]
Arnold, D. [3 ]
Bennouna, J. [4 ]
Kubicka, S. [5 ]
Walzer, S. [1 ]
Ngoh, C. [6 ]
机构：
[1] AiM Assessment Med GmbH, Lorrach, Germany
[2] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria
[3] Univ Hosp, Hubertus Wald Tumor Ctr, UCCH, Eppendorf, Germany
[4] Inst Cancerol Quest, Nantes, Saint Herblain, France
[5] Hannover Med Sch, D-30623 Hannover, Germany
[6] F Hoffmann La RocheLa Roche AG, Basel, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [42] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K. W.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher R.
    Hall, Peter S.
    ONCOLOGIST, 2017, 22 (06): : 694 - 699
  • [43] What is the benefit for patients suffering from metastatic colorectal cancer (mCRC) after bevacizumab-based regimen (BBR), cetuximab-based regimen (CBR), and panitumumab (P)?
    Metges, J.
    Ramee, J.
    Raoul, J.
    Gourlaouen, A.
    Porneuf, M.
    Capitain, O.
    Achour, N.
    Egreteau, J.
    Douillard, J.
    Grude, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer
    Tamura, Shingo
    Kusaba, Hitoshi
    Kubo, Naoki
    Ijichi, Kayo
    Tsuchihashi, Kenji
    Komoda, Masato
    Uchino, Keita
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    MEDICAL ONCOLOGY, 2014, 31 (03)
  • [45] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, J. A.
    Stuart, K.
    Zhu, A.
    Fuchs, C.
    Bhargava, P.
    Earle, C.
    Blaszkowsky, L.
    Lawrence, C.
    Battu, S.
    Ryan, D. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [46] PHARMACOECONOMICS ANALYSIS OF TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN BRAZIL
    Tonon, L. M.
    Secoli, S. R.
    VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
  • [47] COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
    Schmidt, E.
    Bischoff, H. G.
    Heigener, D. F.
    Stanisic, S.
    Walzer, S.
    VALUE IN HEALTH, 2010, 13 (07) : A271 - A271
  • [48] Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
    Buchler, Tomas
    Chloupkova, Renata
    Poprach, Alexandr
    Fiala, Ondrej
    Kiss, Igor
    Kopeckova, Katerina
    Dusek, Ladislav
    Veskrnova, Veronika
    Slavicek, Lubomir
    Kohoutek, Milan
    Finek, Jindrich
    Svoboda, Marek
    Petruzelka, Lubos
    Melichar, Bohuslav
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 359 - 368
  • [49] Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
    Janku, Filip
    Wheler, Jennifer J.
    Hong, David S.
    Kurzrock, Razelle
    TARGETED ONCOLOGY, 2013, 8 (03) : 183 - 188
  • [50] Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
    Filip Janku
    Jennifer J. Wheler
    David S. Hong
    Razelle Kurzrock
    Targeted Oncology, 2013, 8 : 183 - 188
12345